Tyra Biosciences, Inc. 8-K

What Happened

• Tyra Biosciences, Inc. announced its financial results for the quarter ended March 31, 2026 by issuing a press release on May 13, 2026 and furnished that release as Exhibit 99.1 to an 8-K (Item 2.02, Results of Operations and Financial Condition). The Form 8-K states the press release is furnished, not “filed,” under General Instruction B.2 of Form 8-K.

Key Details

• Filing date: May 13, 2026.
• Reporting period: Quarter ended March 31, 2026 (Q1 2026).
• Press release attached as Exhibit 99.1 to the 8-K (also includes Inline XBRL cover page 104).
• Form signed by Alan Fuhrman, Chief Financial Officer, on behalf of Tyra Biosciences.

Why It Matters

• The company has publicly released its quarterly earnings information; investors should review the attached press release for the specific financial figures (revenue, expenses, net loss/profit, cash position and any management commentary or guidance).
• Because the release is furnished (not filed), it is not subject to certain liabilities under Section 18 of the Exchange Act and is not automatically incorporated by reference into other filings. This is a procedural detail but relevant for legal/filing-readers assessing disclosure status.

Keywords: earnings, quarterly results, financial results, press release, 8-K, Tyra Biosciences.